TuHURA Biosciences Files 8-K on Financials
Ticker: HURA · Form: 8-K · Filed: Apr 1, 2026 · CIK: 0001498382
Sentiment: neutral
Topics: financial-reporting, 8-k, results-of-operations
TL;DR
TUHURA dropped an 8-K on 4/1/26 with financial results. Check it out.
AI Summary
TuHURA Biosciences, Inc./NV filed an 8-K on April 1, 2026, reporting results of operations and financial condition. The filing includes financial statements and exhibits, with the primary document being an iXBRL 8-K.
Why It Matters
This filing provides investors with crucial updates on TuHURA Biosciences' financial performance and operational status as of April 1, 2026.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not inherently indicate new risks.
Key Players & Entities
- TuHURA Biosciences, Inc./NV (company) — Filer
- 0001498382 (company) — CIK Number
- 2026-04-01 (date) — Filing Date and Period of Report
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates Item 2.02: Results of Operations and Financial Condition, but the specific details of the results are not provided in the summary information.
What are the key documents included in this filing?
The filing includes an iXBRL 8-K document, an EX-99.1 document, and a complete submission text file, along with XBRL taxonomy extension schema and extracted XBRL instance documents.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 1, 2026, at 08:00:08.
What is TuHURA Biosciences, Inc./NV's business address?
The business address is 10500 UNIVERSITY CENTER DR. SUITE 110 TAMPA FL 33612.
What is the SIC code for TuHURA Biosciences, Inc./NV?
The SIC code is 2834 for Pharmaceutical Preparations, categorized under 03 Life Sciences.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2026-04-01 08:00:08
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
Filing Documents
- hura-20260401.htm (8-K) — 51KB
- hura-ex99_1.htm (EX-99.1) — 41KB
- 0001193125-26-135766.txt ( ) — 210KB
- hura-20260401.xsd (EX-101.SCH) — 30KB
- hura-20260401_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On April 1, 2026, TuHURA Biosciences, Inc. (the "Company" or "TuHURA") issued a press release reporting its financial results for the year ended December 31, 2025, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Document 99.1 Press Release, dated April 1, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: April 1, 2026 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer